Please find enclosed herewith Financial Results for Q4FY202526
GPTHEALTH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
GPT Healthcare reported Q4 FY26 revenue of ₹12,637.18 lakhs, up 24.6% YoY from ₹10,140.22 lakhs. Full year revenue grew 16.1% to ₹47,254.70 lakhs from ₹40,709.14 lakhs. However, full year PAT declined 14.4% to ₹4,272.05 lakhs from ₹4,992.17 lakhs, with EPS falling to ₹5.15 from ₹6.08. Finance costs nearly doubled to ₹824.04 lakhs from ₹347.15 lakhs. Operating cash flow improved to ₹8,116.10 lakhs from ₹6,739.61 lakhs. The Board proposed a final dividend of ₹1.50 per share (15%) in addition to the interim dividend of ₹1.00 already paid, totaling ₹2.50 per share. Statutory auditors S.R. Batliboi & Co. LLP issued an unmodified opinion.
While Q4 showed strong revenue growth, the full-year PAT decline of 14.4% and higher finance costs may concern investors. The stock could face pressure if markets focus on profitability decline despite revenue growth.